It is with great pride and appreciation that we announce that MPI (Media Pharmaceutica Indonesiana) has officially been accredited as a SINTA 2 journal, effective from Volume 5, Number 2, Year 2023 through Volume 10, Number 1, Year 2028.

This distinguished recognition reflects our steadfast commitment to academic excellence, rigorous peer-review processes, and the advancement of pharmaceutical science and research. We extend our sincere gratitude to all authors, reviewers, and readers whose contributions have been instrumental in attaining this milestone.

In line with our efforts to ensure long-term sustainability and continual improvement in the quality of our publications, we are implementing an Article Processing Charge (APC) for all accepted manuscripts, effective immediately. The APC policy is as follows:

• USD 100 or
• IDR 1,000,000 (one million rupiah)

This fee applies to all manuscripts that have been accepted for publication and authors may choose to pay the APC in either USD or IDR, based on their preference. Upon acceptance of a manuscript, an official invoice will be issued to the corresponding author, along with detailed instructions for making the payment. Accepted payment methods include bank transfer and other secure electronic payment options, which will be specified in the invoice.

Additionally, please be informed that the Author Guidelines have been revised to align with the journal’s updated standards and policies. We strongly encourage all prospective authors to carefully consult the new guidelines prior to manuscript submission, to ensure compliance with formatting, structure, and ethical requirements.
We greatly value your understanding and cooperation in supporting the sustainability and continued improvement of our publication process, and we look forward to your continued contributions to MPI (Media Pharmaceutica Indonesiana).

With highest regards,
Editorial Board
MPI (Media Pharmaceutica Indonesiana)